Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials
A pioneering once-a-day pill that regenerates nerve cell connections damaged by ALS has been FDA-approved for ongoing clinical trials. The drug is now being given to those with ALS and could be a watershed moment in the treatment of the fatal disease.
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, affects nerve cells in the brain and spinal cord, called motor neurons, that control voluntary muscle movements like walking, talking, and breathing. As the neurons die and can’t send messages to the muscles, loss of muscle control worsens over time and is eventually fatal.
The US Food and Drug Administration (FDA) has approved several drugs that help manage symptoms or slow the disease’s progress, but there’s no current treatment that reverses the progression of ALS. In short, there’s no cure. That’s where Spinogenix, Inc. comes in.
Spinogenix, a clinical-stage biopharmaceutical company, has developed SPG302, a unique once-a-day pill that regenerates the gaps, called synapses, between neurons to restore communication. Following promising results from clinical trials to evaluate the drug’s safety, the FDA has approved the company’s Investigational New Drug (IND) application, paving the way for further trials.
Para mais sobre esta noticía vê o post nas nossas redes sociais:
Facebook: O Mundo do Biomédico
Instagram: o_mundo_biomedico
Comentários
Enviar um comentário